Senescent B Cells Drive Cancer Immunotherapy Resistance in Esophageal Cancer

This groundbreaking study reveals why immunotherapy fails in many esophageal cancer patients by identifying a previously unknown cellular saboteur. Using single-cell RNA sequencing from 24 surgical samples, researchers discovered that patients with poor immunotherapy responses harbor high levels of senescent EGR1+ B cells in their tumors.

These senescent B cells represent immune cells that have stopped dividing but continue secreting harmful inflammatory molecules called SASP (senescence-associated secretory phenotype). The study showed these cells recruit TREM2+ tumor-associated macrophages that actively suppress the immune system's ability to fight cancer. Trajectory analysis revealed EGR1+ B cells sit at the terminal end of a cellular senescence pathway, essentially representing immune cells that have aged out of useful function.

The clinical implications are significant: patients with higher cellular senescence scores had worse overall survival and progression-free survival across multiple cancer types. In esophageal cancer specifically, EGR1+ B cell infiltration correlated strongly with immunotherapy resistance and poor pathological responses.

Most encouragingly, the researchers identified fisetin—a natural flavonoid found in strawberries and apples—as an effective senolytic agent that can selectively eliminate these problematic B cells. In preclinical models, fisetin treatment enhanced immunotherapy efficacy by clearing senescent cells and restoring anti-tumor immunity.

This work provides both a new biomarker for predicting immunotherapy response and a potential therapeutic strategy. The findings suggest that combining senolytics like fisetin with standard immunotherapy could significantly improve outcomes for esophageal cancer patients, particularly older individuals who may have accumulated more senescent immune cells.